

February 11, 2025

To,

BSE Limited, 25, P. J. Towers, Dalal Street, Mumbai - 400 001

Ref: Company Scrip Code: 532834

To,

The Manager, Listing Department,

National Stock Exchange of India Ltd., Exchange Plaza, Bandra Kurla Complex, Bandra (East), Mumbai- 400051

Ref: Symbol: CAMLINFINE | | Series: EQ

Sub: Newspaper Advertisement - Disclosure under Regulation 30 and Regulation 47 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 ("SEBI Listing Regulations")

Dear Sir/Madam,

Pursuant to Regulation 30 and Regulation 47 of the SEBI Listing Regulations as amended, please find enclosed copies of the newspaper publication regarding basis of allotment of Rights Equity Shares issued by the Company.

The said extract was published in Business Standard (English) Mumbai, Business Standard (Hindi) Mumbai and Navshakti (Mumbai), on February 11, 2025.

This will also be hosted on Company's website at https://www.camlinfs.com/.

We request you to take the aforesaid on records.

Encl.: a/a. Thanking you, Yours faithfully,

For Camlin Fine Sciences Limited

Rahul Sawale Company Secretary & V. P. Legal



Camlin Fine Sciences Limited, Floor 2 to 5, In G.S. Point, CST Road, Kalina, Santacruz (East), Mumbai 400 098. CIN: L74100MH1993PLC075361









MPL

MAITHON POWER LIMITED

(Contracts Department) Maithon Power Ltd, Village: Dambhui, PO Barbindia, PIN-828205, District-Dhanbad NOTICE INVITING EXPRESSION OF INTEREST

The Maithon Power Limited invites expression of interest from eligible vendors fo the following packages: **Tender Description** Structural Painting FY-26 at Maithon Power Limited at Maithon Power Limited, Jharkhand (Rate contract for One Year)

Jharkhand For details of pre-qualification requirements, bid security, purchasing of tender documen etc., please visit our website URL-https://www.tatapower.com/tender Eligible vendors willing to participate may submit their expression of interest along with the tender fee for issue of bid document latest by 20th Feb 2025.

U#1 NEW LCI COMMISSIONING ACTIVITY at Maithon Power Limited.



JUBILANT BIOSYS LIMITED

(CIN: U24110UP1998PLC029591) Registered Office: Plot 1A, Sector 16A, Noida, 201301, Uttar Pradesh, India Tel: +91 120 4361000 Website: www.iubilantbiosvs.com

NOTICE

Pursuant to the provisions of Section 201 of the Companies Act, 2013 ('the Act'), the Company intends to make an application to the Central Government under Section 196, 197, 203 read with Schedule V and other applicable provisions, if any, of the Act and the Rules made thereunder, for seeking its approval towards appointment of Mr. Giuliano Perfetti (DIN: 09357368) (Non-Resident) appointed as Chief Executive Officer and Managing Director of the Company for a period of 3 years effective from January 27, 2025 in terms of the approval conferred by the Board of Directors of the Company at its Meeting held on Wednesday, October 23, 2024 and by the Shareholders at their Extra Ordinary General Meeting held on Monday, December 2, 2024.

For Jubilant Biosys Limited

Irfan Ali

Company Secretary Date: February 10, 2025 Place: Noida Membership No.: A20129

Balaxi Pharmaceuticals Limited

Registered Office: Plot No.409, H. No. 8-2-293, Maps Towers, 3rd Floor, Phase-III, Road No. 81, Jubilee Hills, Hyderabad, Telangana, India - 500096.

CIN: L25191TG1942PLC121598 | Phone: +91 40 23555300 | Email: secretarial@balaxi.in | Website: www.balaxipharma.in

EXTRACT OF UNAUDITED STANDALONE AND CONSOLIDATED FINANCIAL RESULTS FOR THE QUARTER ENDED DECEMBER 31, 2024

						(Rs.in Lakhs	unless specified)	
			STANDALONE		CONSOLIDATED			
SI. No.	Particulars	QuarterEnded 31.12.2024	Nine Months Ended 31.12.2024	Quarter Ended 31.12.2023	QuarterEnded 31.12.2024	Nine Months Ended 31.12.2024	Quarter Ended 31.12.2023	
		Un- audited	Un- audited	Un- audited	Un- audited	Un- audited	Un- audited	
1	Total Income from Operations	1,115.83	5,133.94	1,269.99	7,329.13	21,629.51	6,078.50	
2	Net profit/(loss) for the period (before tax, exceptional* and/or extraordinary items)	233.44	642.66	76.65	606.92	1,900.69	1,263.19	
3	Net profit/(loss) for the period before tax (after exceptional* and/or extraordinary items)	233.44	642.66	76.65	606.92	1,900.69	1,427.30	
4	Net profit/(loss) for the period after tax (after exceptional* and/or extraordinary items)	174.32	478.13	48.82	536.28	1,643.26	1,359.36	
5	Total Comprehensive Income for the period [Comprising profit/(loss) for the period (after tax) and other comprehensive income (after tax)]	174.32	478.13	48.82	765.14	1,945.19	953.79	
6	Paid-up Equity Share Capital [Face value of Rs. 2 each]	1,104.15	1,104.15	1,023.02	1,104.15	1,104.15	1,023.02	
7	Reserves (excluding Revaluation Reserve) as per the Audited Balance Sheet of the previous year							
8	Earnings Per Share (of Rs.2/- each) 1. Basic (amount in Rs.)	0.32	0.87	0.10	0.97	2.98	2.66	
l	2. Diluted (amount in Rs.)	0.32	0.87	0.09	0.97	2.98	2.64	
⊢	Note:	0.32	0.67	0.09	0.97	2.96		

Place: Hyderabad

Date: February 10,2025

a) The above is an extract of the detailed format of Financial Results for the quarter ended December 31, 2024, filed with the Stock Exchange under Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The full format of the Statement of Unaudited Standalone and Consolidated Financial Results is available on the website of the Stock Exchange at www.nseindia.com (NSE) and on the Company's website at www.balaxipharma.in.

b) The above Unaudited Standalone and Consolidated Financial Results were reviewed by the Audit Committee and approved by the Board of Directors at their meetings held on February 10,2025. The said Financial Results are prepared in accordance with the Indian Accounting Standards (Ind AS) as prescribed under Section 133 of



For and on behalf of the Board of Directors **Balaxi Pharmaceuticals Limited**

Ashish Maheshwari Managing Director DIN: 01575984



STATEMENT OF UNAUDITED FINANCIAL RESULTS FOR THE QUARTER ENDED DECEMBER 31, 2024

₹in lakhs

	Quarte	r Ended	Year Ended
Particulars	31st December 2024	31st December 2023	31st March 2024
	Unaudited	Unaudited	Audited
1 Total Income from operations	1,580.16	1,507.87	5,990.29
Net Profit for the period (before Tax, Exceptional and / or Extraordinary items)	294.25	319.85	1,593.27
Net Profit for the period before Tax (after Exceptional and / or Extraordinary items)	294.25	319.85	1,593.27
4 Net Profit for the period after Tax (after Exceptional and / or Extraordinary items)	230.98	236.60	1,229.27
Total Comprehensive Income for the period [Comprising Profit/(Loss) for the period (after tax and Other Comprehensive Income (after tax)]	237.57	243.42	1,222.25
Paid up Equity Share Capital (Face Value of Rs. 10/- Each)	2,500.00	2,500.00	2,500.00
7 Other Equity excluding Revaluation Reserves	9,063.46	7,870.96	8,406.83
8 Securities Premium Account	-	-	
9 Net Worth	11,563.46	10,370.96	10,906.83
10 Paid up Debt Capital / Outstanding Debt	24,402.43	18,022.16	19,583.08
Outstanding Redeemable Preference Shares	-	-	-
12 Debt Equity Ratio	2.11	1.74	1.80
Earnings per equity share (Face Value of Rs. 10/-Each) (for continuing and discontinued operations)			
Basic (Rs.)* Diluted (Rs.)*	0.92 0.92	0.95 0.95	4.92 4.92
14 Capital Redemption Reserve	NA	NA	NA
15 Debenture Redemption Reserve	NA	NA	NA
16 Debt Service Coverage Ratio	NA	NA	NA
17 Interest Service Coverage Ratio	NA	NA	NA
*Not annualised			

Note:

Place: Cochin


Date: 10.02.2025

a) The above is an extract of the detailed format of Audited Financial Results filed with Stock Exchanges under Regulation 52 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The full format of the Audited Financial Results are available on the website of BSE Limited (www.bseindia.com) where the Securities of the Company are listed and on the website of the Company at www.mvafl.com

b) For the other line items referred in regulation 52(4)of the Listing Regulation, pertinent disclosures have been made to the BSE limited and can be accessed on www.bseindia.com

c) These finanancial results have been prepared in accordance with Regulation 52 of the SEBI (Listing and Other Disclosure

Requirements) Regulation 2015, as amended



DIN: 00019016



Registered Office: Muthoot Chambers, Opp. Saritha Theatre, Banerji Road, Kochi, Ernakulam - 682 018, Kerala, India; Corporate Office: 5th and 6th Floor Midhun Tower, K P Vallon Road, Kadavanthra, Ernakulam - 682020, Kerala, India Tel: +91 75938 64418

Email: cs@mvafl.com, Website: www.mvafl.com



MIRAE ASSET FINANCIAL SERVICES (INDIA) PRIVATE LIMITED

CIN: U65999MH2020PTC337638
Registered Office: Unit No. 606, 6th Floor, Windsor Bldg, Off CST Road, Kalina, Santacruz – 400098 Website: www.miraeassetfin.com; Email:compliance@miraeassetfin.com; Phone: + 91 22 6900 5000

EXTRACT OF THE STANDALONE UNAUDITED FINANCIAL RESULTS FOR THE NINE MONTHS ENDED DECEMBER 31, 2024

		Quarter	rended	Year ended
SI. No.	Particulars	December 31, 2024 (Unaudited)	December 31, 2023 (Unaudited)	March 31, 2024 (Audited)
1	Total Income from Operations	3,756.98	2,133.46	7,174.09
2	Net Profit / (Loss) for the period (before Tax, Exceptional and / or Extraordinary items")	174.00	(26.85)	790.61
3	Net Profit / (Loss) for the period before Tax (after Exceptional and / or Extraordinary items")	174.00	(26.85)	790.61
4	Net Profit / (Loss) for the period after Tax (after Exceptional and / or Extraordinary items*)	395.28	(72.23)	559.64
5	Total Comprehensive Income for the period	2.39	9.26	(3.84)
6	Paid up Equity Share Capital	33,200.00	33,200.00	33,200.00
7	Reserves (excluding Revaluation Reserve)	1,384.80	200.89	359.21
8	Securities Premium Account	-	-	-
9	Net worth	34,584.80	33,400.89	33,559.21
10	Paid up Debt Capital / Outstanding Debt	82,123.33	29,845.10	50,346.18
11	Outstanding Redeemable Preference Shares	-	-	-
12	Debt Equity Ratio	2.37	0.89	1.50
13	Earnings per Share (of ₹10 each) (for continuing and discontinued operations) -			
	1. Basic:	0.12	(0.02)	0.17
	2. Diluted:	0.12	(0.02)	0.17
14	Capital Redemption Reserve	-	-	-
15	Debenture Redemption Reserve	-	-	-
16	Debt Service Coverage Ratio	NA	NA	NA
17	Interest Service Coverage Ratio	NA.	NA	NA

- Exceptional and/ or Extraordinary items adjusted in the Statement of Profit and Loss in accordance with Ind AS Rules/ AS Rules, whichever is applicable

Place: Mumbai Date: February 07, 2025

- The above is an extract of the detailed format of quarterly financial results filed with the BSE Limited under regulation 52 of the Listing Regulations. The full format of the quarterly financial results is available on the website of the BSE Limited (www.bseindia.com) and the Company (www.miraeassetfin.com).
- b) For the other line items referred in regulation 52(4) of the Listing Regulations, pertinent disclosures have been made to the BSE Limited and can be accessed on the URL (www.bseindia

For and on behalf of the Board of Directors of

Mirae Asset Financial Services (India) Private Limited

Krishna Kanhaiya Director & CÉO

This is only an advertisement for information purposes only and not for publication, distribution or release directly or indirectly outside India. This is not an announcement for the offer document. All capitalized terms used and not defined herein shall have the meaning assigned to them in the letter of offer dated January 9, 2025 (the "Letter of Offer" or "LOF") filed with the Stock Exchanges, namely BSE Limited ("BSE") and National Stock Exchange of India Limited ("NSE" and together with BSE, "Stock Exchanges") and the Securities and Exchange Board of India ("SEBI")



Camlin Fine Sciences Limited

Consultants Private Limited". The name of our Company was changed to "Camlin Fine Chemicals Private Limited" and a fresh certificate of incorporation consequent upon change of name was issued by the RoC on June 1, 2006. The name of our Company was changed to "Camlin Fine Chemicals Limited" and a fresh certificate of incorporation consequent upon change of name on conversion to public limited company was issued by the RoC on August 11, 2006. The name of our Company was then changed to "Camlir Fine Sciences Limited" and a fresh certificate of incorporation consequent upon change of name was issued by the RoC on August 27, 2011

Registered Office: Floor 2 to 5, Building "In G. S. Point", Plot No. VIII, Private Layout Scheme, Opp. University Campus, C.S.T. Road, Kalina, Santacruz (East), Mumbai, Maharashtra, 400098 Contact person: Rahul Sawale, Company Secretary and Compliance Officer

Registered Office Telephone: +91 022 6700 1000 | E-mail id: secretarial@camlinfs.com | Website: https://www.camlinfs.com Corporate Identity Number: L74100MH1993PLC075361

SH DANDEKAR, ANAGHA DANDEKAR, CAMART FINANCE LIMITED, VIBHA AG CAFCO CONSULTANTS LIMITED, MK FALCON AGRO TECH PRIVATE LIMITED, INFINITY HOLDINGS, INFINITY DIRECT HOLDINGS,
INFINITY DIRECT HOLDINGS SIDECAR I, INFINITY PORTFOLIO HOLDINGS AND ANFIMA NV

ISSUE OF 2.04.25.805 FULLY PAID UP EQUITY SHARES OF FACE VALUE OF ₹1 EACH OF OUR COMPANY (THE "RIGHTS EQUITY SHARES") FOR CASH AT A PRICE OF ₹110/- PER RIGHTS EQUITY SHARE (INCLUDING A PREMIUM OF ₹109/- PER RIGHTS EQUITY SHARE) ÀGGREGATING TO ₹ 2,24,68,38,550/- ON A RIGHTS BASIS TO THE ELIGIBLE EQUITY SHAREHOLDERS OF OUR COMPANY IN THE RATIO OF 5 (FIVE) RIGHTS EQUITY SHARES FOR EVERY 41 (FORTY-ONE) FULLY PAID UP EQUITY SHARES HELD BY THE ELIGIBLE EQUITY SHAREHOLDERS ON THE RECORD DATE, THAT IS WEDNESDAY, JANUARY 8, 2025 ("RECORD DATE") (THE

BASIS OF ALLOTMENT

The Board of Directors of Camlin Fine Sciences Limited wishes to thank all its Equity Shareholders, members and investors for their response to the Issue which opened for subscription on January 17, 2025 and closed on January 27, 2025 with the last date for on-market renunciation of Rights Entitlements on January 21, 2025. Out of the total 7,420 Applications for 3,39,18,255 Rights Equity Shares, through the Application Supported by Blocked Amount ("ASBA"), 443 Applications for 4,77,265 Rights Equity Shares were rejected due to technical reasons as disclosed in the Letter of Offer. The total number of valid Applications received were 6,977 Applications for 3,34,40,990 Rights Equity Shares, which was 163.72% of the number of Rights Equity Shares Allotted under the Issue. In accordance with the Letter of Offer, the Basis of Allotment was finalised on January 30, 2025 by the Company, in consultation with the Lead Managers, the Registrar to the Issue and BSE, the Designated Stock Exchange for the Issue. The Securities Issue and Allotment Committee of the Company, passed the resolution on January 31, 2025 took on record the Basis of Allotment and approved the allotment of 2,04,25,805 Right Equity Shares to successful Applicants. In the Issue, 439 Rights Equity Shares have been kept in abeyance. All valid Applications after the rejection of bids received from non-Eligible Shareholders and technical rejections have been considered for Allotment.

1. Information regarding Applications received (including ASBA applications received):

Category	Application	s Kreceivea	Eq	uity Snares Applied to	ſ		Equity Snares allotted	
	Number	%	Number	Value (Rs.)	%	Number	Value (Rs.)	%
Non Renouncees	7,335	98.85%	3,12,94,291	3,44,23,72,010.00	92.26%	1,89,24,596	2,08,17,05,560.00	92.65%
Renouncees	85	1.15%	26,23,964	28,86,36,040.00	7.74%	15,01,209	16,51,32,990.00	7.35%
Total	7,420	100.00%	3,39,18,255	3,73,10,08,050.00	100.00%	2,04,25,805	2,24,68,38,550.00	100.00%
2 Basis of Allotmen	t·							

No. of valid CAFs (including No. of Equity Shares accepted No. of Equity Shares accepted and Category **Total Equity Shares** accepted and allotted ASBA applications) received and allotted against Entitlement allotted against Additional applied (A+B) (A) (B) Number Number Number Number 33,87,811 Non Renouncees 6.899 1.55.36.785 1.89.24.596 Renouncees 15.01.209 15,01,209

33,87,811 6,984 1,70,37,994 2,04,25,805 Intimations for Allotment / unblock / rejection cases: The dispatch of Allotment Advice cum Unlocking intimation to the investors, as applicable, commenced and completed on February 7, 2025. The instructions to SCSBs for unblocking of funds in case of ASBA Applications were given on January 30, 2025. The listing application was filed with Stock Exchanges on February 3, 2025 and subsequently the listing approvals were received from both BSE and NSE on February 5, 2025 and February 6, 2025, respectively. The credit of Rights Equity Shares in dematerialized form to respective demat accounts of Allottees was completed on February 7, 2025. For further details, see "TERMS OF ISSUE -ALLOTMENT ADVICE OR REFUND/ UNBLOCKING OF ASBA" on page 312 of the Letter of Offer. Upon receipt of listing and trading approvals, the Rights Equity Shares Allotted in the Issue will commence trading on or before February 11, 2025 and shall be traded under the same ISIN INF052I01032 as the existing Equity Shares. In accordance with the SEBI circular bearing reference no SEBI/HO/CFD/DIL2/CIR/P/2020/13 dated January 22, 2020 the request for extinguishment of rights entitlement has been sent to

NSDL & CDSL on February 6, 2025. INVESTORS MAY PLEASE NOTE THAT THE RIGHTS EQUITY SHARES CAN BE TRADED ON THE STOCK EXCHANGES ONLY IN DEMATERIALISED FORM. DISCLAIMER CLAUSE OF SEBI: Submission of the LOF to SEBI should not in any way be deemed or construed that SEBI has cleared or approved the LOF. Investors are

advised to refer to the full text of the 'Disclaimer Clause of SEBI' beginning on page 276 of the LOF. DISCLAIMER CLAUSE OF BSE (Designated Stock Exchange): It is to be distinctly understood that the permission given by BSE Limited should not, in anyway, be deemed or

construed that the Letter of Offer has been cleared or approved by BSE Limited; nor does it certify the correctness or completeness of any of the contents of the Letter of Offer. Investors are advised to refer to the Letter of Offer for the full text of the 'Disclaimer Clause of BSE' beginning on page 280 of the LOF. DISCLAIMER CLAUSE OF NSE: It is to be distinctly understood that the permission given by NSE should not in any way be deemed or construed that the Letter of Offer has been

cleared or approved by NSE nor does it certify the correctness or completeness of any of the contents of the Letter of Offer. Investors are advised to refer to the Letter of Offer for the full text of the 'Disclaimer clause of NSE' on page 280 of the LOF. LEAD MANAGERS TO THE ISSUE

∶←NTRUM

Level 9, Centrum House, C.S.T Road, Vidyanagari Marg Kalina, Santacruz East, Mumbai 400098

Telephone: +91 22 4215 9000; E-mail: camlin.rights@centrum.co.in Investor grievance e-mail id: igmbd@centrum.co.in

Contact person: Pooja Sanghvi/Tarun Parmani Website: www.centrum.co.in; SEBI Registration No: INM000010445

REGISTRAR TO THE ISSUE

MUFG

Date: February 10, 2025

(Previously known as, "Link Intime India Private Limited") C-101, 1st Floor, 247 Park, Lal Bahadur Shastri Marg,

Vikhroli (West) Mumbai 400 083, Maharashtra, India Telephone: +91 81081 14949; Email: camlin.rightsissue@linkintime.co.in Investor grievance e-mail: camlin.rightsissue@linkintime.co.in

Contact Person: Shanti Gopalakrishnan Website: www.linkintime.co.in; SEBI Registration No.: INR000004058

InCred Capital

InCred Capital Wealth Portfolio Managers Private Limited Unit No 1203, 12th Floor, B Wing, The Capital C-70, G Block, BKC, Bandra (E), Mumbai 400051

Telephone: +91-22-4161-1500; **E-mail:** camlin.rights@incredcapital.com Investor grievance e-mail id: customer.grievance@incredcapital.com Contact person: Harish Mallawat; Website: https://www.incredequities.com/ SEBI Registration No: INM000012865

COMPANY SECRETARY AND COMPLIANCE OFFICER

Rahul Sawale

Floor 2 to 5. Building in G.S. Point, Plot No. VIII, Opp. University Campus, C.S.T. Road, Kalina, Santacruz East, Mumbai 400098

Telephone: +91 9920882621; E- mail: rahul.sawale@camlinfs.com Investors may contact the Registrar to the Issue or our Company Secretary and Compliance

Investors may contact the Registrar to the Issue or our Company Secretary and Compilance Officer for any pre Issue or post-Issue related matter. All grievances relating to the ASBA process may be addressed to the Registrar to the Issue, with a copy to the SCSB, giving full details such as name, address of the Applicant, contact number(s), e-mail address of the sole/ first holder, folio number or demat account number, number of Rights Equity Shares applied for, amount blocked, ASBA Account number and the Designated Branch of the SCSB where the Application Form, or the plain paper application, as the case may be, was submitted by the Investors along with a photocopy of the acknowledgement slip. For details on the ASBA process, please see "Terms of the Issue" on page 285 of this LOF

THE LEVEL OF SUBSCRIPTION SHOULD NOT BE TAKEN TO BE INDICATIVE OF EITHER THE MARKET PRICE OF THE EQUITY SHARES ON LISTING OR THE BUSINESS PROSPECTS OF CAMLIN FINE SCIENCES LIMITED.

> For CAMLIN FINE SCIENCES LIMITED On behalf of the Board of Directors

Rahul Sawale Company Secretary and Compliance Officer

Camlin Fine Sciences Limited has filed a Letter of Offer dated January 9, 2025 with BSE, the designated stock exchange, NSE and SEBI, The LOF is available on the website of SEBI at www.sebi.gov.in, National Stock Exchange of India Limited at www.nseindia.com, BSE Limited at www.bseindia.com, the website of the Lead Managers to the Issue, i.e. Centrum Capital Limited at www.centrum.co.in and InCred Capital Wealth Portfolio Managers Private Limited at https://www.incredequities.com/, website of the Company at https://www.camlinfs.com and website of the Registrar at www.linkintime.co.in. Investors should note that investment in equity shares involves a degree of risk and for details relating to the same, please see the section entitled "Risk Factors" on page 26 of the LOF.

This announcement has been prepared for publication in India and may not be released in the United States. This announcement does not constitute an offer for sale in any jurisdiction, including United States. The Rights Entitlements and the Right Equity Shares have not been, and will not be registered under the United States Securities Act of 1933. as amended (the "U.S. Securities Act") and may not be offered or sold within the United States, except pursuant to an exemption from, or in a transaction not subject to, the registration requirements of the U.S. Securities Act and applicable state securities laws. Accordingly, the Rights Entitlements (including their credit) and the Rights Equity Shares are only being offered and sold outside the United States in "offshore transactions" as defined in and in reliance on Regulation S under the U.S. Securities Act and the applicable laws of the jurisdiction where those offers and sales occur.



CHL LIMITED

Regd. Office: Hotel The Suryaa, New Friends Colony, New Delhi 110025 Tel.: 91-11-26835070, 47808080, Fax: 26836288, E-mail: chl@chl.co.in CIN No: L55101DL1979PLC009498



EXTRACT OF UNAUDITED FINANCIAL RESULTS FOR THE PERIOD ENDED 31⁵⁷ DECEMBER 2024

Sr.			STANDALONE			CONSOLIDATED)
No.	PARTICULARS	Quarter Ended		Nine Months Ended	Quarter Ended		Nine Months Ended
		31-12-2024	31-12-2023	31-12-2024	31-12-2024	31-12-2023	31-12-2024
		Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	Unaudited
1	Total income from operations(net)	3,120.81	2,625.45	7,970.25	4,227.29	3,751.26	11,277.21
2	Net Profit/(Loss) for the period (before tax & exceptional items)	1,292.43	1,026.70	2,569.10	451.63	285.39	213.44
3	Net Profit/(Loss) for the period (after exceptional items)	1,292.43	1,026.70	2,569.10	451.63	285.39	213.44
4	Net Profit/(Loss) for the period (after tax & exceptional items)	961.33	769.60	1,915.95	120.54	28.29	(439.70)
5	Total comprehensive income for the period [comprising Net Profit/ (Loss) for the period & Other Comprehensive Income/(expense)]	961.33	769.60	1,915.95	209.61	(0.42)	(872.55)
6	Paid-up equity share capital (face value of Rs. 2/- each)	1,096.37	1,096.37	1,096.37	1,096.37	1,096.37	1,096.37
7	Reserves excluding Revaluation Reserves**	_	-	-	-	-	-
8	Earning Per Share (a) Basic and Diluted (fully paid up equity share of Rs. 2/- each)	1.75	1.40	3.50	0.38	(0.00)	(1.59)

* Reserves for standalone as on 31.03.2024, is Rs. 14304.34 Lacs and for consolidated is Rs. (12581.08) Lacs

NOTES:

- The above is an extract of the detailed format of quarter & half year ended 30.09.2024 filed with the Stock Exchange under Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The full format of quarter & nine months ended 31.12.2024 are available on the websites of the Bombay Stock Exchange ((www.bseindia.com) and on the Company's website (www.chl.co.in).
- The results for the quarter & nine months ended 31.12.2024 have been subjected to limited review by the statutory auditors of the company.

Place : New Delhi Date: 10th February, 2025

CHL LIMITED (Luv Malhotra) Managing Director DIN 00030477

This is only an advertisement for information purposes only and not for publication, distribution or release directly or indirectly outside India. This is not an announcement for the offer document. All capitalized terms used and not defined herein shall have the meaning assigned to them in the letter of offer dated January 9, 2025 (the "Letter of Offer" or "LOF" filed with the Stock Exchanges, namely BSE Limited ("BSE") and National Stock Exchange of India Limited ("NSE" and together with BSE, "Stock Exchanges") and the Securiti and Exchange Board of India ("SEBI").



Camlin Fine Sciences Limited

Consultants Private Limited". The name of our Company was changed to "Camlin Fine Chemicals Private Limited" and a fresh certificate of incorporation consequent upon change of name was issued by the RoC on June 1, 2006. The name of our Company was changed to "Camlin Fine Chemicals Limited" and a fresh certificate of incorporation nsequent upon change of name on conversion to public limited company was issued by the Roc on August 11, 2006. The name of our Company was then changed to "Camlin Fine Sciences Limited" and a fresh certificate of incorporation consequent upon change of name was issued by the RoC on August 27, 2011.

Registered Office: Floor 2 to 5, Building "In G. S. Point", Plot No. VIII, Private Layout Scheme, Opp. University Campus, C.S.T. Road, Kalina, Santacruz (East), Mumbai, Maharashtra, 400098 Contact person: Rahul Sawale, Company Secretary and Compliance Officer

Registered Office Telephone: +91 022 6700 1000 | E-mail id: secretarial@camlinfs.com | Website: https://www.camlinfs.com Corporate Identity Number: L74100MH1993PLC075361

PROMOTERS OF OUR COMPANY: ASHISH DANDEKAR, ANAGHA DANDEKAR, CAMART FINANCE LIMITED, VIBHA AGENCIES PRIVATE LIMITED,

CAFCO CONSULTANTS LIMITED, MK FALCON AGRO TECH PRIVATE LIMITED, INFINITY HOLDINGS, INFINITY DIRECT HOLDINGS, INFINITY DIRECT HOLDINGS SIDECAR I, INFINITY PORTFOLIO HOLDINGS AND ANFIMA NV

ISSUE OF 2,04,25,805 FULLY PAID UP EQUITY SHARES OF FACE VALUE OF ₹1 EACH OF OUR COMPANY (THE "RIGHTS EQUITY SHARES") FOR CASH AT A PRICE OF₹110/- PER RIGHTS EQUITY SHARE (INCLUDING A PREMIUM OF₹109/- PER RIGHTS EQUITY SHARE) AGGREGATING TO₹2,24,68,38,550/- ON A RIGHTS BASIS TO THE ELIGIBLE EQUITY SHAREHOLDERS OF OUR COMPANY IN THE RATIO OF 5 (FIVE) RIGHTS EQUITY SHARES FOR EVERY 41 (FORTY-ONE) FULLY PAID UP EQUITY SHARES HELD BY THE ELIGIBLE EQUITY SHAREHOLDERS ON THE RECORD DATE, THAT IS WEDNESDAY, JANUARY 8, 2025 ("RECORD DATE") (THE

BASIS OF ALLOTMENT

The Board of Directors of Camlin Fine Sciences Limited wishes to thank all its Equity Shareholders, members and investors for their response to the Issue which opened fo subscription on January 17, 2025 and closed on January 27, 2025 with the last date for on-market renunciation of Rights Entitlements on January 21, 2025. Out of the total 7,420 Applications for 3,39,16,255 Rights Equity Shares, through the Application Supported by Blocked Amount ("ASBA"), 443 Applications for 4,77,265 Rights Equity Shares were rejected due to technical reasons as disclosed in the Letter of Offer. The total number of valid Applications received were 6,977 Applications for 3,34,40,990 Rights Equity Shares which was 163.72% of the number of Rights Equity Shares Allotted under the Issue. In accordance with the Letter of Offer, the Basis of Allotment was finalised on January 30, 2025 by the Company, in consultation with the Lead Managers, the Registrar to the Issue and BSE, the Designated Stock Exchange for the Issue. The Securities Issue and Allotmen Committee of the Company, passed the resolution on January 31, 2025 took on record the Basis of Allotment and approved the allotment of 2.04.25.805 Right Equity Shares to successful Applicants. In the Issue, 439 Rights Equity Shares have been kept in abeyance. All valid Applications after the rejection of bids received from non-Eligible Shareholders and technical rejections have been considered for Allotment.

1. Information regarding Applications received (including ASBA applications received):

Category	Application	s Rreceived	Equity Shares Applied for			Equity Shares allotted			
	Number	%	Number	Value (Rs.)	%	Number	Value (Rs.)	%	
Non Renouncees	7,335	98.85%	3,12,94,291	3,44,23,72,010.00	92.26%	1,89,24,596	2,08,17,05,560.00	92.65%	
Renouncees	85	1.15%	26,23,964	28,86,36,040.00	7.74%	15,01,209	16,51,32,990.00	7.35%	
Total	7,420	100.00%	3,39,18,255	3,73,10,08,050.00	100.00%	2,04,25,805	2,24,68,38,550.00	100.00%	
2. Basis of Allotmen	t:								

Category	No. of valid CAFs (including ASBA applications) received	No. of Equity Shares accepted and allotted against Entitlement (A)	No. of Equity Shares accepted and allotted against Additional applied (B)	Total Equity Shares accepted and allotted (A+B)	
	Number	Number	Number	Number	
Non Renouncees	6,899	1,55,36,785	33,87,811	1,89,24,596	
Renouncees	85	15,01,209	0	15,01,209	
Total	6,984	1,70,37,994	33,87,811	2,04,25,805	

Intimations for Allotment / unblock / rejection cases: The dispatch of Allotment Advice cum Unlocking intimation to the investors, as applicable, commenced and completed on February 7, 2025. The instructions to SCSBs for unblocking of funds in case of ASBAApplications were given on January 30, 2025. The listing application was filed with Stock Exchanges on February 3, 2025 and subsequently the listing approvals were received from both BSE and NSE on February 5, 2025 and February 6, 2025, respectively. The cred of Rights Equity Shares in dematerialized form to respective demat accounts of Allottees was completed on February 7, 2025. For further details, see "TERMS OF ISSUE - ALLOTMENT ADVICE OR REFUND/ UNBLOCKING OF ASBA" on page 312 of the Letter of Offer. Upon receipt of listing and trading approvals, the Rights Equity Shares Allotted in the Issue will commence trading on or before February 11, 2025 and shall be traded under the same ISIN INE052I01032 as the existing Equity Shares. In accordance with the SEBI circular bearing reference no SEBI/HO/CFD/DIL2/CIR/P/2020/13 dated January 22, 2020 the request for extinguishment of rights entitlement has been sent to

NSDL & CDSL on February 6, 2025 INVESTORS MAY PLEASE NOTE THAT THE RIGHTS FOLITY SHARES CAN BE TRADED ON THE STOCK EXCHANGES ONLY IN DEMATERIAL ISED FORM

DISCLAIMER CLAUSE OF SEBI: Submission of the LOF to SEBI should not in any way be deemed or construed that SEBI has cleared or approved the LOF. Investors are advised to refer to the full text of the 'Disclaimer Clause of SEBI' beginning on page 276 of the LOF.

DISCLAIMER CLAUSE OF BSE (Designated Stock Exchange): It is to be distinctly understood that the permission given by BSE Limited should not, in anyway, be deemed or construed that the Letter of Offer has been cleared or approved by BSE Limited; nor does it certify the correctness or completeness of any of the contents of the Letter of Offer Investors are advised to refer to the Letter of Offer for the full text of the 'Disclaimer Clause of BSE' beginning on page 280 of the LOF.

DISCLAIMER CLAUSE OF NSE: It is to be distinctly understood that the permission given by NSE should not in any way be deemed or construed that the Letter of Offer has been cleared or approved by NSE nor does it certify the correctness or completeness of any of the contents of the Letter of Offer. Investors are advised to refer to the Letter of Offer fo the full text of the 'Disclaimer clause of NSE' on page 280 of the LOF. LEAD MANAGERS TO THE ISSUE

Rahul Sawale

InCred Capital

SEBI Registration No: INM000012865

COMPANY SECRETARY AND COMPLIANCE OFFICER

C.S.T. Road, Kalina, Santacruz East, Mumbai 400098 Telephone: +91 9920882621: E- mail: rahul.sawale@camlinfs.com

.←NTRUM

Level 9, Centrum House, C.S.T Road, Vidyanagari Marg Kalina, Santacruz East, Mumbai 400098

Telephone: +91 22 4215 9000: E-mail: camlin.rights@centrum.co.in Investor grievance e-mail id: igmbd@centrum.co.in Contact person: Pooja Sanghvi/Tarun Parmani Website: www.centrum.co.in; SEBI Registration No: INM000010445



REGISTRAR TO THE ISSUE

MUFG Intime India Private Limited (Previously known as, "Link Intime India Private Limited") C-101, 1st Floor, 247 Park, Lal Bahadur Shastri Marg, Vikhroli (West) Mumbai 400 083, Maharashtra, India

BUSINESS PROSPECTS OF CAMLIN FINE SCIENCES LIMITED

Telephone: +91 81081 14949; Email: camlin.rightsissue@linkintime.co.in Investor grievance e-mail: camlin.rightsissue@linkintime.co.in Contact Person: Shanti Gopalakrishnan Website: www.linkintime.co.in; SEBI Registration No.: INR000004058

name, address or the Applicant, contact number(s), e-mail address or the sole; first noticer, folio number or demat account number, number of Rights Equity Shares applied for, amount blocked, ASBA Account number and the Designated Branch of the SCSB where the Application Form, or the plain paper application, as the case may be, was submitted by the Investors along with a photocopy of the acknowledgement slip. For details on the ASBA process, please see "Terms of the Issue" on page 285 of this LOF THE LEVEL OF SUBSCRIPTION SHOULD NOT BE TAKEN TO BE INDICATIVE OF EITHER THE MARKET PRICE OF THE EQUITY SHARES ON LISTING OR THE

Investors may contact the Registrar to the Issue or our Company Secretary and Compliance Officer for any pre Issue or post-Issue related matter. All grievances relating to the ASBA process may be addressed to the Registrar to the Issue, with a copy to the SCSB, giving full details such as

name, address of the Applicant, contact number(s), e-mail address of the sole/ first holder, folio

InCred Capital Wealth Portfolio Managers Private Limited Unit No 1203, 12th Floor, B Wing, The Capital C-70, G Block, BKC, Bandra (E), Mumbai 400051

Telephone: +91-22-4161-1500; E-mail: camlin.rights@incredcapital.com

Contact person: Harish Mallawat; Website: https://www.incredequities.com/

Investor grievance e-mail id: customer.grievance@incredcapital.com

Floor 2 to 5, Building in G.S. Point, Plot No. VIII, Opp. University Campus,

For CAMLIN FINE SCIENCES LIMITED

Date: February 10, 2025 Place: Mumba

Rahul Sawale Company Secretary and Compliance Office

Camlin Fine Sciences Limited has filed a Letter of Offer dated January 9, 2025 with BSE, the designated stock exchange, NSE and SEBI. The LOF is available on the website of SEBI at www.sebi.gov.in, National Stock Exchange of India Limited at www.nseindia.com, BSE Limited at www.bseindia.com, the website of the Lead Managers to the Issue, i.e. Centrum Capital Limited at www.centrum.co.in and InCred Capital Wealth Portfolio Managers Private Limited at https://www.incredequities.com/, website of the Company at https://www.camlinfs.com and website of the Registrar at www.linkintime.co.in. Investors should note that investment in equity shares involves a degree of risk and for details relating to the same, please see the section entitled "*Risk Factors*" on page 26 of the LOF.

This announcement has been prepared for publication in India and may not be released in the United States. This announcement does not constitute an offer for sale in an iurisdiction, including United States. The Rights Entitlements and the Right Equity Shares have not been, and will not be registered under the United States Securities Act of 1933 as amended (the "U.S. Securities Act") and may not be offered or sold within the United States, except pursuant to an exemption from, or in a transaction not subject to, the registration requirements of the U.S. Securities Act and applicable state securities laws. Accordingly, the Rights Entitlements (including their credit) and the Rights Equity Shares are only being offered and sold outside the United States in "offshore transactions" as defined in and in reliance on Regulation S under the U.S. Securities Act and the applicable laws of the jurisdiction where those offers and sales occur.

This is only an advertisement for information purposes and not for publication, distribution or release directly or indirectly outside India. This is not an announcement for the offer document. All capitalized terms used and not defined herein shall have the meaning assigned to them in Dhanlaxmi Bank Limited's ("Bank") Letter of Offer dated December 19, 2024 (the **"Letter of Offer")** filed with the stock exchanges, namely BSE Limited ("**BSE"**) and National Stock Exchange of India Limited ("NSE" and together with BSE, the "Stock Exchanges") and the Securities Exchange Board of India ("SEBI").

DhanlaxmiBank

Our Bank was originally incorporated as 'The Dhanalakshmi Bank Limited' on November 14, 1927, under the Indian Companies Act, 1913 and a certificate of incorporation was granted to our Bank by the Assistant Registrar of Joint Stock Companies, India. It became a scheduled commercial bank in 1977 under the Second Schedule of the Reserve Bank of India Act, 1934. Subsequently, the name of our Bank was changed to 'Dhanlaxmi Bank Limited' pursuant to which a fresh certificate of incorporation was granted on August 10, 2010, by the Registrar of Companies Kerala & Lakshadweep at Kochi ("RoC").

Registered Office: Dhanalakshmi Building, Naickanal, Thrissur 680 001, Kerala, India Corporate Office: Punkunnam, Thrissur - 680 002, Kerala, India Contact Person: Venkatesh. H, Company Secretary and Compliance Officer

Tel: 0487-2999711; E-mail: investors@dhanbank.co.in; Website: www.dhanbank.com Corporate Identity Number: L65191KL1927PLC000307

OUR BANK IS A PROFESSIONALLY MANAGED COMPANY AND DOES NOT HAVE A PROMOTER

ISSUE OF 14.16.86,767 EQUITY SHARES OF FACE VALUE OF ₹10 EACH OF OUR BANK (THE "RIGHTS EQUITY SHARES") FOR CASH AT A PRICE OF ₹21.00 PER RIGHTS EQUITY SHARE (INCLUDING A PREMIUM OF ₹11.00 PER RIGHTS EQUITY SHARE) AGGREGATING TO ₹297.54 CRORE ON A RIGHTS BASIS TO THE ELIGIBLE EQUITY SHAREHOLDERS OF OUR BANK IN THE RATIO OF 14 RIGHTS EQUITY SHARES FOR EVERY 25 FULLY PAID-UP EQUITY SHARES HELD BY THE ELIGIBLE EQUITY SHAREHOLDERS ON FRIDAY, DECEMBER 27, 2024 ("RECORD DATE") (THE "ISSUE"). FOR FURTHER DETAILS, SEE "TERMS OF THE ISSUE" ON PAGE 242 OF THE LETTER OF OFFER.

FOR PRIVATE CIRCULATION TO THE ELIGIBLE EQUITY SHAREHOLDERS OF DHANLAXMI BANK LIMITED ONLY

BASIS OF ALLOTMENT

The Board of Directors of the Bank would like to thank all investors for their response to the Issue, which opened for subscription on Wednesday, January 08, 2025 and closed on Tuesday, January 28, 2025 and the last date for market renunciation was on Thursday, January 23, 2025. Out of the total 21,584 applications for 232,663,802 Rights Equity Shares, 1,503 Applications for 3,322,179 Rights Equity Shares were rejected due to technical reasons as disclosed in the Letter of Offer. The total number of valid Applications received was 20,081 for 229,341,623 Rights Equity Shares, which was 161.87% of the number of Rights Equity Shares Allotted under the Issue.

In accordance with the Letter of Offer, the Basis of Allotment was finalised on Tuesday, February 4, 2025, in consultation with National Stock Exchange of India Limited ("NSE"), the Designated Stock Exchange, the Lead Manager to the Issue and the Registrar to the Issue.

The Board of Directors of the Bank at its meeting held on Tuesday, February 4, 2025 took on record the Basis of Allotment and approved the allotment of 141,686,767 Rights Equity Shares to successful applicants. In the Issue, no Rights Equity Shares have been kept in abeyance. All valid Applications, after rejection of bids on technical rejections have been considered for

1. The break-up of valid Applications received through ASBA (after technical rejections) is given below:

Category	Applications Received		Rights Ed	Rights Equity Shares Applied for			Rights Equity Shares allotted			
	Number %		Number	Value (₹)	%	Number	Value (₹)	%		
Eligible	21,035	97.46%	209,195,858	4,393,089,603.00	89.91%	133,952,646	2,813,005,566.00	94.54%		
Equity										
Shareholders										
Renouncees	549	2.54%	23,467,944	492,826,824.00	10.09%	7,734,121	162,416,541.00	5.46%		
Total	21,584	100.00%	232,663,802	4,885,916,427.00	100.00%	141,686,767	2,975,422,107.00	100.00%		

Basis of Allotment

Category	No. Of Valid Applications Received	No. Of Shares under valid Applications	No. Of Rights Equity Shares accepted and Allotted against Rights Entitlement (A)	No. Of Rights Equity Shares accepted and Allotted against Additional Rights Equity Shares applied for (B)	Total Rights Equity Shares accepted and Allotted (A+B)
Eligible Equity Shareholders	19,532	205,873,679	80,566,618	53,386,028	133,952,646
Renouncees	549	23,467,944	7,734,121	0	7,734,121
Total	20,081	229,341,623	88,300,739	53,386,028	141,686,767

Out of a total of 21,584 Applications received, 1,503 Applications were rejected on technical grounds.

Intimation for Allotment/refund/rejections: The dispatch of allotment order cum refund intimation and intimation for rejection, as applicable, to the Investors has been completed on February 7, 2025. The instructions to SCSBs for unblocking of funds in case of ASBA applicants were given on February 4, 2025. The listing application was filed with BSE and NSE on February 5, 2025 and subsequently the listing approvals were received from BSE and NSE on February 5, 2025 and February 6, 2025, respectively. Pursuant to the listing and trading approvals granted by NSE and BSÉ, the Rights Equity Shares Allotted in the Issue is expected to commence trading on BSE and NSE with effect from February 11, 2025. In accordance with SEBI circular bearing no. SEBI/HO/CFD/PoD-1/P/CIR/2024/0154 dated November 11, 2024, the request for extinguishment of rights entitlement has been sent to the National Securities Depository Limited and Central Depository Services (India) Limited on February 5, 2025.

The credit of Rights Equity Shares in dematerialised form to respective demat accounts of Allottees was completed on February 7, 2025. The Rights Equity Shares allotted to resident Eligible Equity Shareholders holding Equity Shares in physical form and who have not provided details of their respective demat accounts, have been credited to the demat suspense account, in accordance with the terms of Letter of Offer. Such Eligible Equity Shareholders are required to send, among other details of their demat account to our Company or the Registrars within six (6) months from the Allotment date, to get the Rights Equity Shares transferred in their demat account. In case non-receipt of demat account, our Company shall conduct a sale of such Rights Equity Shares lying in the demat suspense account on the floor of the Stock Exchanges at the prevailing market price and remit the proceeds of such sale (net of brokerage, applicable taxes and administrative and incidental charges) to the bank account mentioned by the resident Eligible Equity Shareholders in their respective Application forms and the form for which the application payment was made. For further details, please refer to "Terms of the Issue - Credit of Rights Entitlements in demat accounts of Eligible Equity Shareholders" on page 256 of the Letter of Offer.

INVESTORS MAY PLEASE NOTE THAT THE RIGHTS EQUITY SHARES CAN BE TRADED ON THE STOCK EXCHANGES ONLY IN DEMATERIALISED FORM

DISCLAIMER CLAUSE OF SEBI: It is to be distinctly understood that submission of Letter of Offer to SEBI should not in, anyway, be deemed or construed that SEBI has cleared or approved the Letter of Offer. The investors are advised to refer to the full text "Disclaimer Clause of SEBI" beginning on page 236 of the Letter of Offer.

DISCLAIMER CLAUSE OF BSE: It is to be distinctly understood that submission of Letter of Offer to BSE Limited should not, in anyway, be deemed or construed that the Letter of Offer has been cleared or approved by BSE Limited; nor does it certify the correctness or completeness of any of the contents of the Letter of Offer. The investors are advised to refer to the full text "Disclaimer Clause of the BSE" beginning on page 239 of the Letter of Offer.

DISCLAIMER CLAUSE OF NSE (DESIGNATED STOCK EXCHANGE): It is to be distinctly understood that submission of Letter of Offer to NSE Limited should not, in anyway, be deemed or construed that the Letter of Offer has been cleared or approved by NSE; nor does it certify the correctness or completeness of any of the contents of the Letter of Offer. The investors are advised to refer to the full text "Disclaimer Clause of NSE" beginning on page 240 of the Letter of Offer.

EAD MANAGER TO THE ISSUE	REGISTRAR TO THE ISSUE	COMPANY SECRETAR COMPLIANCE OFF
BOBCAPS TRUST I INNOVATION I EXCELLENCE	▲ KFINTECH	Dhanlaxmi Bank
B CAPITAL MARKETS LIMITED 4, B Wing, 17 th Floor,	KFIN TECHNOLOGIES LIMITED Selenium Tower B,	Venkatesh. H, Company Secretary and

1704 Parinee Crescenzo, Plot No. C -38/39, G Block, Bandra Kurla Complex, Bandra (East), Mumbai 400 051,

BOB

Maharashtra, India Tel: +91 22 6138 9353 E-mail: dlb.rights@bobcaps.in Investor Grievance ID: investorgrievance@bobcaps.in Website: www.bobcaps.in Contact person: Nivedika Chavan Plot No.31 & 32. Financial District. Nanakramguda, Serilingampally, Hyderabad, Rangareddi - 500 032, Telangana, India **Tel:** +91 1800 309 4001/ + 91 40 6716 2222

E-mail: dhanlaxmi.rights@kfintech.com Investor Grievance E-mail: einward.ris@kfintech.com Website: www.kfintech.com Contact Person: M. Murali Krishna SEBI Registration No.: INM000009926 SEBI Registration No.: INR000000221

Compliance Officer DHANLAXMI BANK LIMITED Registered Office: Dhanalakshmi Building, Naickanal, Thrissur 680 001, Kerala, India Corporate Office: Punkunnam, Thrissur - 680 002, Kerala, India

COMPLIANCE OFFICER

DhanlaxmiBank

Tel: 0487-2999711 E-mail: investors@dhanbank.co.in Website: www.dhanbank.com Corporate Identity Number: L65191KL1927PLC000307

THE LEVEL OF SUBSCRIPTION SHOULD NOT BE TAKEN TO BE INDICATIVE OF EITHER THE MARKET PRICE OF THE EQUITY SHARES OR THE BUSINESS PROSPECTS OF THE BANK

Investors may contact the Registrar to the Issue or our Company Secretary and Compliance Officer for any pre-Issue or post-Issue related matters. All grievances relating to the ASBA process may be addressed to the Registrar to the Issue, with a copy to the SCSB (in case of ASBA process), giving full details such as name, address of the Applicant, contact number(s), e-mail address of the sole/ first holder, folio number or demat account number, number of Rights Equity Shares applied for, amount blocked (in case of ASBA process), ASBA Account number and the Designated Branch of the SCSB where the Application Form, or the plain paper application, as the case may be, to be submitted by the Investors along with a photocopy of the acknowledgment slip (in case of ASBA process). For details on the ASBA process, please see the section entitled "Terms of the Issue" on page 242 of the Letter of Offer.

> On behalf of Board of Directors For Dhanlaxmi Bank Limited

Date: February 10, 2025 Venkatesh. H Place: Thrissur, Kerala Company Secretary and Compliance Officer

Dhanlaxmi Bank Limited has undertaken a rights issue of its Equity Shares and has in this regard filed a Letter of Offer dated December 19, 2024 with SEBI and the Stock Exchanges. The Letter of Offer is available on the website of SEBI at www.sebi.gov.in, the Stock Exchanges, i.e., BSE at www.bseindia.com and NSE at www.nseindia.com, and on the website of Lead Manager to the Issue, i.e., BOB Capital Markets Limited at www.bobcaps.in. Investors should note that investment in the Rights Equity Shares involves a degree of risk and for details relating to the same, please see section titled "Risk Factors" beginning on page 18 of the Letter of Offer.

This announcement does not constitute an offer of the Rights Equity Shares for sale in any jurisdiction, including the United States, and the Rights Equity Shares may not be offered or sold in the United States absent registration under the US Securities Act of 1933 or an exemption from registration. Any public offering of the Equity Shares to be made in the United States will be made by means of a prospectus that may be obtained from the Company and that will contain detailed information about the Company and management, as well as financial statements. However, the Rights Equity Shares are not being offered or sold in the United States.



बॉम्बे ऑक्सिजन इन्व्हेस्टमेंटस् लिमिटेड

सीआयएन : एल६५१००एमएच१९६०पीएलसी०११८३५

२२/बी, मित्तल टॉवर, २१०, निरमन पॉईंट, मुंबई-४०० ०२१

इमेल आयडी : contact@bomoxy.com, वेबसाईटः www.bomoxy.com

३१ डिसेंबर, २०२४ रोजी संपलेल्या तिमाही आणि नऊ महिन्यांकरिता अलेखापरिक्षित वित्तीय निष्कर्षाचा उतारा

(रु. लाखात)

		संपलेली तिमाही		संपलेले र	1 ऊ महिने	संपलेले वर्ष
तपशील	३१.१२.२०२४ (अलेखापरिक्षित)	३०.०९.२०२४ (अलेखापरिक्षित)	३१.१२.२०२३ (अलेखापरिक्षित)	३१.१२.२०२४ (अलेखापरिक्षित)	३१.१२.२०२३ (अलेखापरिक्षित)	३१.०३.२०२४ (लेखापरिक्षित)
प्रवर्तनातून एकूण उत्पन्न (निब्बळ)	(१,८५४.०७)	२,३९६.८२	२,२३१.७७	३,४४३.२८	५,८१८.१५	७,०८३.९७
वर्षाकरिता निव्वळ नफा/(तोटा) (कर, अपवादात्मक आणि/िकंवा अनन्यसाधारण बार्बीपूर्वी) करपूर्व वर्षाकरिता निव्वळ नफा/(तोटा) (अपवादात्मक	(१,८२७.६५)	२,३५३.२७	२,१८७.९८	३,३७९.३१	५,६८५.८०	७,०२२.१०
आणि/किंवा अनन्यसाधारण बाबीनंतर)	(१,८२७.६५)	२,३५३.२७	२,१८७.९८	३,३७९.३१	५,६८५.८०	७,०२२.१८
करपश्चात वर्षाकरिता निव्वळ नफा/(तोटा) (अपवादात्मक आणि/किंवा अनन्यसाधारण बाबीनंतर)	(१,५४८.०७)	१,८४४.८१	१,७४७.१६	२,९८०.७३	४,८९०.६४	५,७६०.०९
वर्षासाठी एकूण सर्वसमावेशक उत्पन्न (करोत्तर वर्षासाठी नफा किंवा (तोटा) आणि करोत्तर इतर सर्वसमावेशक उत्पन्न धरून)	(२,९७६.६९)	३,०८८.८४	४,०१९.१०	३,४३६.६४	१०,८७२.०२	१३,०१५.९।
समभाग भांडवल	१५०.००	१५०.००	१५०.००	१५०.००	१५०.००	१५०.०
प्रत्येकी रु. १००/- ची प्रती भाग प्राप्ती (ईपीएस) - मूलभूत आणि सौम्यिकृत (अवार्षिक)	(१,०३२.०५)	१,२२९.८७	१,१६४.७७	१,९८७.१५	३,२६०.४३	३,८४०.०१

- १) वरील माहिती म्हणजे सुधारित सेबी (लिस्टिंग ऑब्लिगेशन्स अँड डिस्क्लोजर रिक्वायरमेंटस्) रेग्युलेशन्स, २०१५ च्या रेग्युलेशन ३३ अंतर्गत स्टॉक एक्स्चेंजमध्ये सादर केलेल्य तिमाही आणि नऊ महिन्यांकरिता निष्कर्षांच्या तपशिलवार विवरणाचा एक उतारा आहे. संपलेल्या तिमाही आणि नऊ महिने वित्तीय निष्कर्षांचे संपूर्ण विवरण स्टॉक एक्स्चेंजचे संकेतस्थळ बीएसईची www.bseindia.com आणि कंपनीचे संकेतस्थळ www.bomoxy.com वर उपलब्ध आहे.
- २) ३१ डिसेंबर, २०२४ रोजी संपलेल्या तिमाही आणि नऊ महिन्यांकरिता कंपनी वरील अलेखापरिक्षित वित्तीय निष्कर्ष १० फेब्रुवारी, २०२५ रोजी झालेल्या त्यांच्या सभेत लेखापरीक्षण समितीद्वारे पुनर्विलोकीत करण्यात आले संचालक मंडळाकडे शिफारस केले आणि त्यानंतर संचालक मंडळाद्वारे मंजुर करण्यात आले.
- ३) सुधारित सेबी (लिस्टींग ऑब्लिगेशन्स अँड डिस्क्लोजर रिक्वायरमेंटस्) रेग्युलेशन, २०१५ च्या रेग्युलेशन ३३ अन्वये आवश्यक असल्याने वैधानिक लेखापरीक्षकांनी ३१ डिसेंबर, २०२४ रोजी संपलेल्या तिमाही आणि नऊ महिन्यांकरिता वित्तीय निष्कर्ष पुनर्विलोकित केले आहेत.
- ४) वित्तीय निष्कर्ष कंपनी अधिनियम, २०१३ च्या कलम १३३ अन्वये विहित सुधारित (इंडएएस) कंपनीज (इंडियन अकाऊंटिंग स्टॅण्डर्डस्) रुल्स २०१५ आणि लागू इतर लेखा पद्धती आणि धोरणानुसार तयार करण्यात आले आहेत.
- ५) मागील तिमाहीची तुलनात्मक वित्तीय माहिती ही चालू तिमाहीच्या आकडेवारीशी सुसंगत होण्यासाठी आवश्यक तेथे पुनर्गठित/पुनरीचित करण्यात आली आहे.

संचालक मंडळाच्या आदेशावरुन हेमा रेंगानाथन

पूर्ण वेळ संचालक डीआयएन: ०८६८४८८१



ठिकाण: मुंबई

दिनांक : १० फेब्रुवारी, २०२५

Suraj Estate Developers Limited CIN: L99999MH1986PLC040873

Regd Off. 301, 3rd Floor, Aman Chambers, Veer Savarkar Marg, Opp. Bengal Chemicals, Prabhadevi Mumbai, Maharashtra - 400 025

			Quarter Ended		Nine Mon	lions except EPS Year Ended	
Sr.	Particulars	31-Dec-24	30-Sep-24	31-Dec-23	31-Dec-24	31-Dec-23	31-Mar-24
No.		(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Audited)
1	Total Income from Operations	1,718.23	1,096.39	1,061.49	4,160.87	3,126.65	4,157.04
2	Net Profit/(Loss) for the period						
	(before Tax, Exceptional and/or Extraordinary items)	260.15	437.17	220.94	1,101.33	643.44	938.69
3	Net Profit/(Loss) for the period before tax						
	(after Exceptional and/or Extraordinary items)	260.15	437.17	220.94	1,101.33	643.44	938.69
4	Net Profit/(Loss) for the period after tax and non controlling						
	interest (after Exceptional and/or Extraordinary items)	199.84	318.32	165.74	819.49	480.25	674.91
5	Total Comprehensive Income for the period [Comprising Profit						
	/(Loss) for the period (after tax and non controlling interest)						
	and Other Comprehensive Income (after tax)]	199.86	318.12	165.73	819.65	480.49	673.48
6	Equity Share Capital (Face Value per Share of ₹ 5/- each)	231.37	214.31	214.31	214.31	214.31	214.31
7	Earning Per Share (Face Value of ₹ 5/- each) (for continuing						
	and discontinuing operations) [Not annualised for quarters]						
	1. Basic (in ₹)	4.23	7.18	5.03	17.36	15.00	19.39
	2. Diluted (in ₹)	4.20	7.18	5.03	17.31	15.00	19.39

LINALIDITED CONSOLIDATED FINANCIAL RESULT FOR THE QUARTER ENDED 31ST DECEMBER 2024

*Net off elimination on consolidation due to equity shares held by subsidiary company. Notes to consolidated unaudited financial results:

- 1 The above consolidated unaudited financial results have been reviewed and recommended by Audit Committee and approved by the Board of Directors at their respective meetings held on held on February 10, 2025. The statutory auditors of the Company have carried out limited review of the results for the quarter and nine month ended December 31, 2024. 2 The above consolidated audited financial results have been prepared in accordance with recognition and measurement principles laid down in the applicable Indian
- Accounting Standards (Ind AS) as prescribed under Section 133 of the Companies Act, 2013 ("the Act"), as amended, read with relevant rules thereunde 3 The Group is exclusively operating in the business of Real Estate and other allied activities. This in the context of Indian Accounting Standard (Ind AS - 108) - "Operating
- Segment" constitutes single operating segment. The Group does not have operations outside India, hence Geographical Segment is not applicable. 4 Subsequent to quarter end, the Holding Company has allotted 34,12,277 Equity shares of ₹714 each (including premium of ₹709 each) on preferential basis in accordance
- with the provision of the Securities and Exchange Board of India (Issue of Capital and Disclosure Requirements) Regulations, 2018 and other applicable rules/regulations/guidelines. 5 Subsequent to quarter end, the Holding Company has allotted 13,30,000 Convertible warrants of ₹750 each in accordance with the provision of the Securities and Exchange
- Board of India (Issue of Capital and Disclosure Requirements) Regulations, 2018 and other applicable rules/regulations/guidelines 6 The figures for the previous period/year have been regrouped or rearranged or reclassified wherever considered necessary to make them comparable with current periods/
- years classification

UNAUDITED STANDALONE FINANCIAL RESULT FOR THE QUARTER ENDED 31ST DECEMBER 2024								
All amount in INR Millions except EPS								
Sr. No.		Quarter Ended			Nine Months Ended		Year Ended	
	Particulars	31-Dec-24	30-Sep-24	31-Dec-23	31-Dec-24	31-Dec-23	31-Mar-24	
NO.		(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Audited)	
1	Total Income from Operations (Net)	1,555.48	1,138.75	998.21	4,076.74	2,845.39	3,868.51	
2	Profit/(Loss) before Tax	289.85	444.30	219.11	1,168.34	793.18	985.62	
3	Profit/(Loss) after Tax	221.26	323.36	165.13	869.34	590.72	713.79	
E 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1								

For and on behalf of the Board Suraj Estate Developers Limited

Thomas Meenathakonil Rajan Chairman & Managing Director (DIN: 00634576)

Place: Mumbai Date:10th February 2025

Adfactors 615/25



फायबरवेब (इंडिया) लिमिटेड

सीआयएन नं. : एल२५२०९डीडी१९८५पीएलसी००४६९४ नोंदणीकृत कार्यालय : एअरपोर्ट रोड, कडैया, नानी दमण, दमण (यु.टी.)-३९६ २१० वेबसाईट : www.fiberwebindia.com, ई-मेल आयडी: fiberweb@fiberwebindia.com, द. क्र. ०२६०-२२२१४५८, फॅक्स क्र. ०२६०-२२२०७५८,

३१.१२.२०२४ रोजी संपलेली ३री तिमाही आणि नऊ महिन्यांकरिता अलिप्त अलेखापरिक्षित वित्तीय निष्कर्षांचे विवरण

							(रु. लाखांत)		
		अलिप्त							
	तपशिल	संपलेली तिमाही			संपलेले	संपलेले वर्ष			
		३१.१२.२०२४	३०.०९.२०२४	३१.१२.२०२३	३१.१२.२०२४	३१.१२.२०२३	39.03.7078		
		अलेखापरिक्षित	अलेखापरिक्षित	अलेखापरिक्षित	अलेखापरिक्षित	अलेखापरिक्षित	लेखापरिक्षित		
१	प्रवर्तनातून एकूण उत्पन्न (इतर उत्पन्न धरून)	२५२१.३५	२५६४.८७	१४९५.१०	७६४२.०७	६५९४.१०	८६८९.२५		
2	कालावधीसाठी निव्वळ नफा/(तोटा) (कर, अपवादात्मक आणि/किंवा अनन्यसाधारण बार्बीपूर्वी #)	879.03	४०४.१९	१२५.६७	१२११.०३	४२३.४५	७३६.१०		
¥	कालावधीसाठी निव्वळ नफा/(तोटा) (करपूर्व अपवादात्मक आणि/किंवा अनन्यसाधारण बाबींनंतर #)	४२७.०३	४०४.१९	१२५.६७	१२११.०३	४२३.४५	७३६.१०		
8	कालावधीसाठी करोत्तर निव्वळ नफा/ (तोटा) (अपवादात्मक आणि/किंवा अनन्यसाधारण बाबीनंतर #)	३५५.०३	३५४.१९	१५४.२८	९९९.०३	\$98.80	७२६.९६		
ч	कालावधीसाठी एकूण सर्वसमावेशक उत्पन्न (कालावधीसाठी नफा/ (तोटा) (करोत्तर) आणि इतर सर्वसमावेशक उत्पन्न (करोत्तर) धरून)	३५५.०३	३५४.१९	१५४.२८	९९९.०३	₹७४.४८	७२६.९६		
ξ	समभाग भांडवल	२८७९.१७	२८७९.१७	२८७९.१७	२८७९.१७	२८७९.१७	२८७९.१७		
G	मागील वर्षीच्या लेखापरिक्षित ताळेबंदात दाखवल्याप्रमाणे राखीव (पुनर्मुल्यांकित राखीव वगळून)	-	-	-	-	-	१३२५५.३१		
۷	प्रति समभाग प्राप्ती (प्रत्येकी रु. १०/- चे) (अखंडित आणि खंडित कामकाजासाठी)	-	-	-	-	_	-		
	(ए) मूलभूत	१.२३	१.२३	0.48	3.80	१.३०	२.५२		
	(बी) सौम्यिकृत	१.२३	१.२३	०.५४	₹.४७	१.३०	२.५२		

- आणि संचालक मंडळाद्वारे १० फेब्रुवारी, २०२५ रोजी झालेल्या सभेत मंजुर करण्यात आले. सांविधिक लेखापरीक्षकांनी ३१.१२.२०२४ रोजी संपलेली ३री तिमाही आणि नऊ महिन्यांसाठी अलेखापरिक्षित वित्तीय निष्कर्षांचे मर्यादित पुनर्विलोकन केले आहे.
- वरील माहिती म्हणजे सिक्युरिटीज ॲन्ड एक्स्चेंज बोर्ड ऑफ इंडिया (लिस्टींग ऑब्लिगेशन्स ॲंड डिस्क्लोजर रिकायरमेंटस्) रेग्युलेशन्स, २०१५ च्या रेग्युलेशन ३३ अंतर्गत स्टॉक एक्सचेंजकडे सादर केलेल्या वित्तीय निष्कर्षांच्या तपशिलवार विवरणाचा एक उतारा आहे. वित्तीय निष्कर्षांचे संपूर्ण विवरण स्टॉक एक्सचेंज वेबसाईटस् (www.bseindia.com)(www.nseindia.com) वर आणि कंपनीची वेबसाईट (www.fiberwebindia.com) वर
- वरील निष्कर्ष हे निगम व्यवहार मंत्रालयाने अधिसूचित केल्यानुसार इंडियन अकाऊंटिंग स्टॅंडर्डस् (इंड एएस) च्या अनुपालनात आहेत ४. संलग्न मागील तिमाहीची आकडेवारी ही तुलनात्मक बनविण्यासाठी आवश्यक तेथे पुनर्गठित/पुनर्वर्गीकृत करण्यात आली आहे.
- ठिकाण : मंबर्ड दिनांक : १० फेब्रुवारी, २०२५



संचालक मंडळाच्या वतीने आणि करिता फायबरवेब (इंडिया) लिमिटेड प्रविण व्ही. शेठ अध्यक्ष आणि संचालक डीआयएन: ००१३८७९७

This is only an advertisement for information purposes only and not for publication, distribution or release directly or indirectly outside India. This is not an announcement for the offer document. All capitalized terms used and not defined herein shall have the meaning assigned to them in the letter of offer dated January 9, 2025 (the "Letter of Offer" or "LOF") filed with the Stock Exchanges, namely BSE Limited ("BSE") and National Stock Exchange of India Limited ("NSE" and together with BSE, "Stock Exchanges") and the Securities and Exchange Board of India ("SEBI")



Camlin Fine Sciences Limited

Our Company was incorporated on November 30, 1993, pursuant to certificate of incorporation issued by RoC, as a private limited company under the name of "Camlicon Consultants Private Limited". The name of our Company was changed to "Camlin Fine Chemicals Private Limited" and a fresh certificate of incorporation consequent upon change of name was issued by the RoC on June 1, 2006. The name of our Company was changed to "Camlin Fine Chemicals Limited" and a fresh certificate of incorporation consequent upon change of name on conversion to public limited company was issued by the RoC on August 11, 2006. The name of our Company was then changed to "Camlin Fine Sciences Limited" and a fresh certificate of incorporation consequent upon change of name was issued by the RoC on August 27, 2011.

Registered Office: Floor 2 to 5, Building "In G. S. Point", Plot No. VIII, Private Layout Scheme, Opp. University Campus, C.S.T. Road, Kalina, Santacruz (East), Mumbai, Maharashtra, 400098 Contact person: Rahul Sawale, Company Secretary and Compliance Officer

Registered Office Telephone: +91 022 6700 1000 | E-mail id: secretarial@camlinfs.com | Website: https://www.camlinfs.com Corporate Identity Number: L74100MH1993PLC075361

ROMOTERS OF OUR COMPANY: ASHISH DANDEKAR, ANAGHA DANDEKAR, CAMART FINANCE LIMITED, VIBHA AGENCIES PRIVATE LIMITED, CAFCO CONSULTANTS LIMITED, MK FALCON AGRO TECH PRIVATE LIMITED, INFINITY HOLDINGS, INFINITY DIRECT HOLDINGS, INFINITY DIRECT HOLDINGS, INFINITY DIRECT HOLDINGS SIDECAR I, INFINITY PORTFOLIO HOLDINGS AND ANFIMA NV

ISSUE OF 2,04,25,805 FULLY PAID UP EQUITY SHARES OF FACE VALUE OF ₹1 EACH OF OUR COMPANY (THE "RIGHTS EQUITY SHARES") FOR CASH AT A PRICE OF ₹110/- PER RIGHTS EQUITY SHARE (INCLUDING A PREMIUM OF ₹109/- PER RIGHTS EQUITY SHARE) AGGREGATING TO ₹ 2,24,68,38,550/- ON A RIGHTS BASIS TO THE ELIGIBLE EQUITY SHAREHOLDERS OF OUR COMPANY IN THE RATIO OF 5 (FIVE) RIGHTS EQUITY SHARES FOR EVERY 41 (FORTY-ONE) FULLY PAID UP EQUITY SHARES HELD BY THE ELIGIBLE EQUITY SHAREHOLDERS ON THE RECORD DATE, THAT IS WEDNESDAY, JANUARY 8, 2025 ("RECORD DATE") (THE

BASIS OF ALLOTMENT

The Board of Directors of Camlin Fine Sciences Limited wishes to thank all its Equity Shareholders, members and investors for their response to the Issue which opened for subscription on January 17, 2025 and closed on January 27, 2025 with the last date for on-market renunciation of Rights Entitlements on January 21, 2025. Out of the total 7,420 Applications for 3,39,18,255 Rights Equity Shares, through the Application Supported by Blocked Amount ("ASBA"), 443 Applications for 4,77,265 Rights Equity Shares were rejected due to technical reasons as disclosed in the Letter of Offer. The total number of valid Applications received were 6,977 Applications for 3,34,40,990 Rights Equity Shares, which was 163.72% of the number of Rights Equity Shares Allotted under the Issue. In accordance with the Letter of Offer, the Basis of Allotment was finalised on January 30, 2025 by the Company, in consultation with the Lead Managers, the Registrar to the Issue and BSE, the Designated Stock Exchange for the Issue. The Securities Issue and Allotment Committee of the Company, passed the resolution on January 31, 2025 took on record the Basis of Allotment and approved the allotment of 2,04,25,805 Right Equity Shares to successful Applicants. In the Issue, 439 Rights Equity Shares have been kept in abeyance. All valid Applications after the rejection of bids received from non-Eligible Shareholders and the properties of the pand technical rejections have been considered for Allotment

1. Information regarding Applications received (including ASBA applications received):

Category	Applications Rreceived		Eq	Equity Shares Applied for			Equity Shares allotted		
	Number %		Number	Value (Rs.)	%	Number	Value (Rs.)	%	
Non Renouncees	7,335	98.85%	3,12,94,291	3,44,23,72,010.00	92.26%	1,89,24,596	2,08,17,05,560.00	92.65%	
Renouncees	85	1.15%	26,23,964	28,86,36,040.00	7.74%	15,01,209	16,51,32,990.00	7.35%	
Total	7,420	100.00%	3,39,18,255	3,73,10,08,050.00	100.00%	2,04,25,805	2,24,68,38,550.00	100.00%	
2. Basis of Allotment:									

2. Basis of Alloument:									
Category	No. of valid CAFs (including ASBA applications) received	No. of Equity Shares accepted and allotted against Entitlement (A)	No. of Equity Shares accepted and allotted against Additional applied (B)	Total Equity Shares accepted and allotted (A+B)					
	Number	Number	Number	Number					
Non Renouncees	6,899	1,55,36,785	33,87,811	1,89,24,596					
Renouncees	85	15,01,209	0	15,01,209					
Total	6,984	1,70,37,994	33,87,811	2,04,25,805					
Intimation for Allaterant Lymbols by Justice and Allaterant Advises and Indepting intimation to the investors of applicable assumption and applicable									

tions for Allotment / unblock / rejection cases: The dispatch of Allotment Advice cum Unlocking intimation to the investors, as applicable, commenced and complete on February 7, 2025. The instructions to SCSBs for unblocking of funds in case of ASBA Applications were given on January 30, 2025. The listing application was filed with Stock Exchanges on February 3, 2025 and subsequently the listing approvals were received from both BSE and NSE on February 5, 2025 and February 6, 2025, respectively. The credit of Rights Equity Shares in dematerialized form to respective demat accounts of Allottees was completed on February 7, 2025. For further details, see "TERMS OF ISSUE -ALLOTMENT ADVICE OR REFUND/ UNBLOCKING OF ASBA" on page 312 of the Letter of Offer. Upon receipt of listing and trading approvals, the Rights Equity Shares Allotted in the Issue will commence trading on or before February 11, 2025 and shall be traded under the same ISIN INE052I01032 as the existing Equity Shares. In accordance with the SEBI circular bearing reference no SEBI/HO/CFD/DIL2/CIR/P/2020/13 dated January 22, 2020 the request for extinguishment of rights en NSDL & CDSL on February 6, 2025.

INVESTORS MAY PLEASE NOTE THAT THE RIGHTS EQUITY SHARES CAN BE TRADED ON THE STOCK EXCHANGES ONLY IN DEMATERIALISED FORM.

DISCLAIMER CLAUSE OF SEBI: Submission of the LOF to SEBI should not in any way be deemed or construed that SEBI has cleared or approved the LOF. Investors are advised to refer to the full text of the 'Disclaimer Clause of SEBI' beginning on page 276 of the LOF.

DISCLAIMER CLAUSE OF BSE (Designated Stock Exchange): It is to be distinctly understood that the permission given by BSE Limited should not, in anyway, be deemed or construed that the Letter of Offer has been cleared or approved by BSE Limited; nor does it certify the correctness or completeness of any of the contents of the Letter of Offer. Investors are advised to refer to the Letter of Offer for the full text of the 'Disclaimer Clause of BSE' beginning on page 280 of the LOF. DISCLAIMER CLAUSE OF NSE: It is to be distinctly understood that the permission given by NSE should not in any way be deemed or construed that the Letter of Offer has been

cleared or approved by NSE nor does it certify the correctness or completeness of any of the contents of the Letter of Offer. Investors are advised to refer to the Letter of Offer for the full text of the 'Disclaimer clause of NSE' on page 280 of the LOF. LEAD MANAGERS TO THE ISSUE

$\mathsf{C} eq \mathsf{N} \, \mathsf{T} \, \mathsf{R} \, \mathsf{U} \, \mathsf{M}$

Centrum Capital Limited

Level 9, Centrum House, C.S.T Road, Vidyanagari Marg Kalina, Santacruz East, Mumbai 400098

Telephone: +91 22 4215 9000; E-mail: camlin.rights@centrum.co.in Investor grievance e-mail id: igmbd@centrum.co.ir

Contact person: Pooja Sanghvi/Tarun Parmani Website: www.centrum.co.in; SEBI Registration No: INM000010445 REGISTRAR TO THE ISSUE



Date: February 10, 2025

Place: Mumba

(Previously known as, "Link Intime India Private Limited") C-101, 1st Floor, 247 Park, Lal Bahadur Shastri Marg,

Vikhroli (West) Mumbai 400 083, Maharashtra, India Telephone: +91 81081 14949; Email: camlin.rightsissue@linkintime.co.in Investor grievance e-mail: camlin.rightsissue@linkintime.co.in

BUSINESS PROSPECTS OF CAMLIN FINE SCIENCES LIMITED.

Contact Person: Shanti Gopalakrishnan Website: www.linkintime.co.in; SEBI Registration No.: INR000004058

InCred Capital

InCred Capital Wealth Portfolio Managers Private Limited Unit No 1203, 12th Floor, B Wing, The Capital

C-70, G Block, BKC, Bandra (E), Mumbai 400051 Telephone: +91-22-4161-1500; E-mail: camlin.rights@incredcapital.com Investor grievance e-mail id: customer.grievance@incredcapital.com Contact person: Harish Mallawat; Website: https://www.incredequities.com/

SEBI Registration No: INM000012865 COMPANY SECRETARY AND COMPLIANCE OFFICER

Floor 2 to 5, Building in G.S. Point, Plot No. VIII, Opp. University Campus, C.S.T. Road, Kalina, Santacruz East, Mumbai 400098 Telephone: +91 9920882621; E- mail: rahul.sawale@camlinfs.com

Investors may contact the Registrar to the Issue or our Company Secretary and Compliance the plain paper application, as the case may be, was submitted by the Investors along with a

photocopy of the acknowledgement slip. For details on the ASBA process, please see "Terms of the Issue" on page 285 of this LOF THE LEVEL OF SUBSCRIPTION SHOULD NOT BE TAKEN TO BE INDICATIVE OF EITHER THE MARKET PRICE OF THE EQUITY SHARES ON LISTING OR THE

> For CAMLIN FINE SCIENCES LIMITED On behalf of the Board of Directors

Sd/ Rahul Sawale

Company Secretary and Compliance Office

Camlin Fine Sciences Limited has filed a Letter of Offer dated January 9, 2025 with BSE, the designated stock exchange, NSE and SEBI. The LOF is available on the website of SEBI at www.sebi.gov.in, National Stock Exchange of India Limited at www.nseindia.com, BSE Limited at www.bseindia.com, the website of the Lead Managers to the Issue, i.e., Centrum Capital Limited at www.centrum.co.in and InCred Capital Wealth Portfolio Managers Private Limited at https://www.incredequities.com/, website of the Company at https://www.camlinfs.com and website of the Registrar at www.linkintime.co.in. Investors should note that investment in equity shares involves a degree of risk and for details relating to the same, please see the section entitled "Risk Factors" on page 26 of the LOF.

This announcement has been prepared for publication in India and may not be released in the United States. This announcement does not constitute an offer for sale in any jurisdiction, including United States. The Rights Entitlements and the Right Equity Shares have not been, and will not be registered under the United States Securities Act of 1933, as amended (the "U.S. Securities Act") and may not be offered or sold within the United States, except pursuant to an exemption from, or in a transaction not subject to, the registration requirements of the U.S. Securities Act and applicable state securities laws. Accordingly, the Rights Entitlements (including their credit) and the Rights Equity Shares are only being offered and sold outside the United States in "offshore transactions" as defined in and in reliance on Regulation S under the U.S. Securities Act and the

applicable laws of the jurisdiction where those offers and sales occur.

KHANDWALA SECURITIES LIMITED

KHANDWALA SECURITIES LIMITED

Registered Office: G-II, Ground Floor, Dalamal House, Nariman Point, Mumbai - 400021. Tel. No: 91-22-40767373; Fax No: 91-22-40767377 Website: www.kslindia.com; Email: investorgrievances@kslindia.com; CIN No.: L67120MH1993PLC070709

EXTRACT OF STATEMENT OF UNAUDITED FINANCIAL RESULTS FOR THE QUARTER AND NINE MONTHS ENDED 31ST DECEMBER, 2024

(₹ In Lakhs)

Sr. Particulars		STANDALONE			CONSOLIDATED			
No.		Quarter Ended	Nine Months Ended	Quarter Ended	Quarter Ended	Nine Months Ended	Quarter Ended	
		31.12.2024	31.12.2024	31.12.2023	31.12.2024	31.12.2024	31.12.2023	
		(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	
1	Total Income from operations	270.02	835.80	216.04	270.02	835.80	216.04	
2	Net Profit / (Loss) for the Period (before Tax, Exceptional and/ or Extraordinary items)	53.38	122.61	25.90	53.36	122.56	25.91	
3	Net Profit / (Loss) for the Period before Tax (after Exceptional and/ or Extraordinary items)	53.38	122.61	25.90	53.36	122.56	25.91	
4	Net Profit / (Loss) for the Period after Tax (after Exceptional and/ or Extraordinary items)	53.95	125.40	26.74	53.92	125.35	26.74	
5	Total Comprehensive Income for the period [Comprising Profit /(Loss) for the period (after tax) and Other comprehensive income (after tax)]	53.95	125.40	26.74	53.92	125.35	26.74	
6	Equity Share Capital	1,525.38	1,525.38	1,525.38	1,525.38	1,525.38	1,525.38	
7	Reserves (excluding Revaluation Reserve as shown in the Balance Sheet of previous year)	-	-	-	-	-	-	
8	Earnings Per Share (of ₹ 10/- each)							
	Basic:	0.35	0.82	0.18	0.35	0.82	0.18	
	Diluted:	0.35	0.82	0.18	0.35	0.82	0.18	

Notes:

- 1) The above is an extract of the detailed format of Standalone and Consolidated Financial Results for the Quarter and Nine Months ended on 31st December 2024, filed with the Stock Exchanges under Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The full format of the Financial Results for the Quarter and Nine Months ended on 31st December 2024 are available on the Stock Exchange Website www.nseindia.com and www.bseindia.com and on the company's website www.kslindia.com.
- 2) The financial results of the Company have been prepared in accordance with the Indian Accounting Standards (Ind AS) prescribed under section 133 of the Companies Act, 2013 read with relevant rules thereunder and in terms of Regulation 33 of the SEBI (Listing Obligation and Disclosure Requirements) Regulation, 2015.

By order of the Board For Khandwala Securities Limited

Paresh Khandwala

Managing Director

Place: Mumbai Dated: February 10, 2025